Waldencast (WALD) Panoramica del titolo
Waldencast plc opera nel settore della bellezza e del benessere negli Stati Uniti, in Canada, Europa, Medio Oriente, India, Australia e Nuova Zelanda. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
WALD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Waldencast plc
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.96 |
| Massimo di 52 settimane | US$3.22 |
| Minimo di 52 settimane | US$0.72 |
| Beta | -0.070 |
| Variazione di 1 mese | 5.62% |
| Variazione a 3 mesi | -46.90% |
| Variazione di 1 anno | -65.43% |
| Variazione a 3 anni | -89.53% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -87.53% |
Notizie e aggiornamenti recenti
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.Recent updates
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Jan 10
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Nov 26Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Nov 26Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Sep 23Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
Aug 21Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
May 14It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Apr 09
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 13Waldencast Plc: Investors Continue To Demand More Growth
Jun 28We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Jun 19Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
May 11Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Apr 07Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
Dec 14Waldencast Acquisition reports Q2 results; reaffirms FY22 guidance
Aug 11Rendimenti per gli azionisti
| WALD | US Personal Products | US Mercato | |
|---|---|---|---|
| 7D | 12.9% | -0.07% | 0.8% |
| 1Y | -65.4% | -15.8% | 27.7% |
Ritorno vs Industria: WALD ha avuto una performance inferiore rispetto al US Personal Products che ha registrato un rendimento -15.8 % nell'ultimo anno.
Rendimento vs Mercato: WALD ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.7 % nell'ultimo anno.
Volatilità dei prezzi
| WALD volatility | |
|---|---|
| WALD Average Weekly Movement | 12.1% |
| Personal Products Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di WALD è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 12% ) di WALD è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2020 | 367 | Michel Brousset | www.waldencast.com |
Waldencast plc opera nel settore della bellezza e del benessere negli Stati Uniti, in Canada, Europa, Medio Oriente, India, Australia e Nuova Zelanda. L'azienda opera attraverso due segmenti, Obagi Medical e Milk Makeup. Offre prodotti per la cura della pelle che minimizzano i segni dell'invecchiamento cutaneo, affrontano le macchie scure, l'iperpigmentazione, le linee sottili e le rughe e proteggono e migliorano il tono e la consistenza della pelle; cosmetici e altri prodotti di bellezza.
Waldencast plc Riepilogo dei fondamenti
| WALD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$114.15m |
| Utili (TTM) | -US$229.75m |
| Ricavi(TTM) | US$272.07m |
0.4x
Rapporto P/S-0.5x
Rapporto P/EWALD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| WALD Conto economico (TTM) | |
|---|---|
| Ricavi | US$272.07m |
| Costo del fatturato | US$89.05m |
| Profitto lordo | US$183.02m |
| Altre spese | US$412.77m |
| Utili | -US$229.75m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.94 |
| Margine lordo | 67.27% |
| Margine di profitto netto | -84.44% |
| Rapporto debito/patrimonio netto | 27.3% |
Come si è comportato WALD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/01 23:35 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Waldencast plc è coperta da 5 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Olivia Tong Cheang | Raymond James & Associates |